Company: HRTX
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0000950170-25-107416
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-08-12
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

Cooperation Agreement

On August 8, 2025, Heron Therapeutics, Inc. (the “ Company”) entered into a Cooperation Agreement (the “ Cooperation Agreement”) with Rubric Capital Management LP (“ Rubric”), regarding certain changes to the composition of the Company’s Board of Directors (the “ Board”) and other related matters.

Pursuant to the terms of the Cooperation Agreement, the Company has agreed to: (1) increase the size of the Board from six to seven directors; (2) appoint a director nominated by Rubric (the “ New Director”) to serve as a director of the Company; (3) include the New Director in the Company’s slate of nominees for the election of directors at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”) and recommend that the Company’s stockholders vote in favor of the New Director's election at the 2026 Annual Meeting.

The Cooperation Agreement includes certain standstill and mutual non-disparagement provisions (subject to certain carveouts and exceptions) that generally remain in place during the period beginning upon the execution of the Cooperation Agreement and ending the earlier of (i) thirty (30) days prior to the nomination deadline for the Company’s 2026 Annual Meeting, (ii) February 12, 2026 and (iii) one hundred and twenty (120) days prior to the first anniversary of the 2025 annual meeting of stockholders.

The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement filed as Exhibit 10.1 hereto and is hereby incorporated by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.